MX9303554A - Peptido similar al glucagon y derivados de insulinotropina. - Google Patents

Peptido similar al glucagon y derivados de insulinotropina.

Info

Publication number
MX9303554A
MX9303554A MX9303554A MX9303554A MX9303554A MX 9303554 A MX9303554 A MX 9303554A MX 9303554 A MX9303554 A MX 9303554A MX 9303554 A MX9303554 A MX 9303554A MX 9303554 A MX9303554 A MX 9303554A
Authority
MX
Mexico
Prior art keywords
derivatives
insulinotropin
truncated
glp
glucagon
Prior art date
Application number
MX9303554A
Other languages
English (en)
Inventor
Eric R Larson
Glenn C Andrews
Gaston O Daumy
Michael L Francoeur
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9303554A publication Critical patent/MX9303554A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a derivados de péptido 1 similar al glucagón (GLP-1), a GLP-1 truncado, a insulinotropina y a insulinotropina truncada, los cuales, tienen un p1 de, aproximadamente 4,0 o menor o un p1 de, aproximadamente, 7,0 0 mayor. Los derivados de GLP-1, de GLP-1 truncado, de insulinotropina e insulinotropina truncada comprendidos dentro del alcance de esta invención, son particularmente adecuados para administración a un mamífero mediante iontoforésis. Igualmente, esta invención se refiere a métodos para potenciar la ación de al insulina en un mamífero con dichos derivados y a un composiciones farmacéuticas que comprenden dichos derivados. Más aún, esta invención se refiere a nuevos empleos de ciertos derivados conocidos de insulinotropina e insulinotropina truncada para potenciar la acción de la insulina en un mamífero mediante al administración iontoforética de dichos derivados.
MX9303554A 1992-06-15 1993-06-15 Peptido similar al glucagon y derivados de insulinotropina. MX9303554A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89907392A 1992-06-15 1992-06-15

Publications (1)

Publication Number Publication Date
MX9303554A true MX9303554A (es) 1994-06-30

Family

ID=25410453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303554A MX9303554A (es) 1992-06-15 1993-06-15 Peptido similar al glucagon y derivados de insulinotropina.

Country Status (19)

Country Link
EP (2) EP0646128A1 (es)
JP (1) JP2575298B2 (es)
KR (1) KR0154880B1 (es)
CN (1) CN1057098C (es)
AU (1) AU671117B2 (es)
BR (1) BR9306551A (es)
CA (1) CA2138161C (es)
CZ (1) CZ315594A3 (es)
FI (1) FI932722L (es)
HR (1) HRP930993A2 (es)
HU (2) HUT64367A (es)
IL (1) IL105928A0 (es)
MX (1) MX9303554A (es)
NO (1) NO944853L (es)
PL (1) PL176007B1 (es)
RU (1) RU2128663C1 (es)
SK (1) SK155694A3 (es)
WO (1) WO1993025579A1 (es)
YU (1) YU41493A (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996017941A2 (en) * 1994-12-07 1996-06-13 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5747453A (en) * 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE445006T1 (de) 1998-08-10 2009-10-15 Us Gov Health & Human Serv Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
PL205713B1 (pl) * 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CN1495198A (zh) * 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
HUP0700151A2 (en) * 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
BRPI0506694A (pt) 2004-01-08 2007-05-02 Theratechnologies Inc análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
ES2328591T3 (es) 2004-04-23 2009-11-16 Conjuchem Biotechnologies Inc. Procedimiento para la purificacion de conjugados de albumina.
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
JP2013532172A (ja) * 2010-07-09 2013-08-15 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド 安定化したインスリン分泌促進ペプチド及び使用方法
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
RS62368B1 (sr) 2015-05-22 2021-10-29 Univ Leland Stanford Junior Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
US20190290772A1 (en) * 2016-06-02 2019-09-26 Indiana University Research And Technology Corporation Glucagon-like peptide-1-t3 conjugates
BR112019010236A2 (pt) 2016-11-21 2019-08-20 Eiger Biopharmaceuticals, Inc formulações tamponadas de exendina (9-39)
WO2018165462A1 (en) * 2017-03-08 2018-09-13 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504246A (ja) * 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
DE69129226T2 (de) * 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
EP0499990B1 (en) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Method for producing cysteine-free peptides
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid

Also Published As

Publication number Publication date
KR0154880B1 (ko) 1998-10-15
EP0646128A1 (en) 1995-04-05
YU41493A (sh) 1996-10-18
HUT64367A (en) 1993-12-28
EP0969016A2 (en) 2000-01-05
WO1993025579A1 (en) 1993-12-23
CN1085913A (zh) 1994-04-27
NO944853D0 (no) 1994-12-14
CA2138161A1 (en) 1993-12-23
HRP930993A2 (en) 1996-12-31
AU4027593A (en) 1994-01-04
RU94046251A (ru) 1996-10-27
KR950701937A (ko) 1995-05-17
SK155694A3 (en) 1995-05-10
CZ315594A3 (en) 1995-07-12
IL105928A0 (en) 1993-10-20
PL176007B1 (pl) 1999-03-31
HU9301739D0 (en) 1993-09-28
FI932722A0 (fi) 1993-06-14
JP2575298B2 (ja) 1997-01-22
CA2138161C (en) 2003-10-21
JPH07504679A (ja) 1995-05-25
BR9306551A (pt) 1998-09-15
RU2128663C1 (ru) 1999-04-10
CN1057098C (zh) 2000-10-04
HU211498A9 (en) 1995-11-28
AU671117B2 (en) 1996-08-15
NO944853L (no) 1994-12-14
FI932722A7 (fi) 1993-12-16
FI932722L (fi) 1993-12-16

Similar Documents

Publication Publication Date Title
MX9303554A (es) Peptido similar al glucagon y derivados de insulinotropina.
BR9106977A (pt) Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero
DE68929217D1 (en) Insulinotropes hormon
DE69434588D1 (de) Verzögerte Freigabe von Insulinotropin (GLP-1)
DK0699686T3 (da) Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid
HUP9903714A2 (hu) GLP-1-származékok
DK1294757T3 (da) Glucagonlignende peptid 1-analoger
BR9915961A (pt) Análogos de glp-1
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
DE69212203D1 (de) Intrakorporale injizierbare Zusammensetzung zum Implantieren von hochkonzentriertem vernetzten Atelokollagen
DK0946191T3 (da) Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
FI954941A0 (fi) Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
DK358384A (da) Farmaceutiske midler til bekaempelse af diabetes mellitus
ES2149768T3 (es) Conjugados de agentes enlazantes de celulas derivados de cc-1065.
MX9402339A (es) Formulacion de proteina.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
IT1235894B (it) Derivati peptidici, loro preparazione e loro impiego come medicamenti, in particolare peptidi della calcitonina
FR2675997B1 (fr) Composition topique anti radicaux libres a base de superoxyde-dismutase et d'un derive phosphonique.
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
AR012853A1 (es) Formulacion inyectable transparente de compuesto anestesico
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
ES2087652T3 (es) Composiciones cosmeticas y/o farmaceuticas y metodos para su uso en proteger tejidos del contacto con metales pesados.

Legal Events

Date Code Title Description
FG Grant or registration